Adoptive t-cell therapy

Patent metadata

Field	Value
Publication number	US-11547748-B2
Application number	US-201716314117-A
Country	US
Kind code	B2
Filing date	Jun 30, 2017
Priority date	Jun 30, 2016
Publication date	Jan 10, 2023
Grant date	Jan 10, 2023

Abstract

The present invention generally relates to T-cells, such as CD8+ T-cells, CD4+ T-cells, CD3+ T-cells, γδ T-cells or natural killer (NK) T-cells, transfected/transduced with a fusion protein which is recruited by the use of trivalent, bispecific antibody molecule which specifically binds to/interacts with the extracellular domain of the fusion protein. More precisely, the present invention relates to a kit comprising the nucleic acid molecules, vectors and/or the fusion proteins of the present invention and the trivalent, bispecific antibody molecules of the present invention. Further aspects of the inventions are expression vectors comprising nucleic acid molecules encoding the fusion proteins as well as the trivalent, bispecific antibody molecules. Further, a process for the production of the trivalent, bispecific antibody molecules of the invention and a medicament/pharmaceutical composition comprising said trivalent, bispecific antibody molecules are described. The invention also provides the use of said trivalent, bispecific antibody molecules in a method for the treatment of particular diseases as well as a pharmaceutical compositions/medicament comprising said trivalent, bispecific antibody molecules, wherein said trivalent, bispecific antibody molecule(s) is (are) to be administered in combination with transduced T-cells comprising the fusion protein of the invention. The invention also provides a method for the treatment of particular diseases.

First claim

The invention claimed is:

1. A trivalent, bispecific antibody molecule which comprises:
(i) a first binding domain binding the extracellular domain of epithelial growth factor receptor variant III (EGFRvIII), wherein the first binding domain comprises a variable heavy chain complementarity determining region 1 (CDR-H1) comprising SEQ ID NO: 9, a variable heavy chain complementarity determining region (CDR-H2) comprising SEQ ID NO: 10, and a variable heavy chain complementarity determining region 3 (CDR-H3) comprising SEQ ID NO: 11; and wherein the first binding domain comprises a variable light chain complementarity determining region 1 (CDR-L1) comprising SEQ ID NO: 12, a variable light chain complementarity determining region 2 (CDR-L2) comprising SEQ ID NO: 13, and a variable light chain complementarity determining region 3 (CDR-L3) comprising SEQ ID NO: 14;
(ii) a second binding domain binding a tumor-specific antigen naturally occurring on the surface of a tumor cell,
wherein the tumor-specific antigen is mesothelin (MSLN), and wherein the second binding domain comprises a CDR-H1 comprising SEQ ID NO: 15, a CDR-H2 comprising SEQ ID NO: 16, a CDR-H3 comprising SEQ ID NO: 17, a CDR-L1 comprising SEQ ID NO: 18, a CDR-L2 comprising SEQ ID NO: 19, and a CDR-L3 comprising SEQ ID NO: 20; or
wherein the tumor-specific antigen is melanoma chondroitin sulfate proteoglycan (MCSP), and wherein the second binding domain comprises a CDR-H1 comprising SEQ ID NO: 221, a CDR-H2 comprising SEQ ID NO: 222, a CDR-H3 comprising SEQ ID NO: 223, a CDR-L1 comprising SEQ ID NO: 224, a CDR-L2 comprising SEQ ID NO: 225, and a CDR-L3 comprising SEQ ID NO: 226; and
(iii) a third binding domain, wherein the third binding domain is the same as the first binding domain or is the same as the second binding domain;
wherein the trivalent, bispecific antibody molecule comprises at least one amino acid sequence selected from the group consisting of SEQ ID NO: 208, SEQ ID NO: 210, SEQ ID NO: 212, and SEQ ID NO: 214.

2. A trivalent, bispecific antibody molecule comprising amino acid sequences SEQ ID NO: 208, SEQ ID NO: 210, SEQ ID NO: 212, SEQ ID NO: 214, or amino acid sequences SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, and SEQ ID NO: 8.

3. A pharmaceutical composition comprising the trivalent, bispecific antibody molecule according to claim 1 .

4. An expression vector comprising nucleic acid sequences encoding the trivalent, bispecific antibody molecule according to claim 1 .

5. The expression vector of claim 4 , which is polycistronic.

6. The expression vector of claim 4 , wherein said vector further comprises a regulatory sequence which is operably linked to said nucleic acid sequences.

7. A host cell transformed with the expression vector according to claim 4 .

8. A method for the production of a trivalent, bispecific antibody, said method comprising: (a) culturing the host cell according to claim 7 under conditions allowing expression of the trivalent, bispecific antibody molecule; and (b) recovering the produced trivalent, bispecific antibody molecule from the host cell culture.

9. A kit comprising the trivalent, bispecific antibody molecule according to claim 1 .

10. The kit according to claim 9 , further comprising a nucleic acid molecule encoding a fusion protein comprising: (1) an extracellular domain of EGFRvIII comprising an amino acid sequence selected from the group consisting of: SEQ ID NO: 52, SEQ ID NO: 76, SEQ ID NO: 78, SEQ ID NO: 152, and SEQ ID NO: 232; (2) a transmembrane domain of CD28; and (3) a CD3zeta stimulatory domain.

11. The kit according to claim 10 , wherein the fusion protein comprises an amino acid sequence selected from the group consisting of: SEQ ID NO: 42, SEQ ID NO: 44, SEQ ID NO: 48, and SEQ ID NO: 50.

12. The kit according to claim 10 , wherein the nucleic acid molecule comprises a nucleotide sequence selected from the group consisting of: SEQ ID NO: 51, SEQ ID NO: 75, SEQ ID NO: 77, SEQ ID NO: 151, and SEQ ID NO: 231.

13. The kit according to claim 10 , wherein the fusion protein comprises at least one co-stimulatory signalling domain comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 56, SEQ ID NO: 60, SEQ ID NO: 66, SEQ ID NO: 68, SEQ ID NO: 69, SEQ ID NO: 72, SEQ ID NO: 121, and SEQ ID NO: 122.

14. A pharmaceutical composition comprising the trivalent, bispecific antibody molecule according to claim 2 .

15. An expression vector comprising nucleic acid sequences encoding the trivalent, bispecific antibody molecule according to claim 2 .

16. The expression vector of claim 15 , which is polycistronic.

17. The expression vector of claim 15 , wherein said vector further comprises a regulatory sequence which is operably linked to said nucleic acid sequences.

18. A host cell transformed with the expression vector according to claim 15 .

19. A method for the production of a trivalent, bispecific antibody, said method comprising: (a) culturing the host cell according to claim 18 under conditions allowing expression of the trivalent, bispecific antibody molecule; and (b) recovering the produced trivalent, bispecific antibody molecule from the host cell culture.

20. A kit comprising the trivalent, bispecific antibody molecule according to claim 2 .

21. The kit according to claim 20 , further comprising a nucleic acid molecule encoding a fusion protein comprising: (1) an extracellular domain of EGFRvIII comprising an amino acid sequence selected from the group consisting of: SEQ ID NO: 52, SEQ ID NO: 76, SEQ ID NO: 78, SEQ ID NO: 152, and SEQ ID NO: 232; (2) a transmembrane domain of CD28; and (3) a CD3zeta stimulatory domain.

22. The kit according to claim 21 , wherein the fusion protein comprises an amino acid sequence selected from the group consisting of: SEQ ID NO: 42, SEQ ID NO: 44, SEQ ID NO: 48, and SEQ ID NO: 50.

23. The kit according to claim 21 , wherein the nucleic acid molecule comprises a nucleotide sequence selected from the group consisting of: SEQ ID NO: 51, SEQ ID NO: 75, SEQ ID NO: 77, SEQ ID NO: 151, and SEQ ID NO: 231.

24. The kit according to claim 21 , wherein the fusion protein comprises at least one co-stimulatory signalling domain comprising an amino acid sequence selected from the group consisting of: SEQ ID NO: 56, SEQ ID NO: 60, SEQ ID NO: 66, SEQ ID NO: 68, SEQ ID NO: 69, SEQ ID NO: 72, SEQ ID NO: 121, and SEQ ID NO: 122.

Assignees

• Hoffmann La Roche
• Ludwig Maximilians Univ Munchen

Inventors

• Klein Christian
• Sustmann Claudio
• Niederfellner Gerhard
• Geiger Martina
• Endres Stefan
• Kobold Sebastian

Classifications

• C07K14/71

  for growth factors; for growth regulators · CPC title

• C07K2317/35

  Valency · CPC title

• C07K2319/33

  fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies · CPC title

• C07K2319/00

  Fusion polypeptide · CPC title

• C07K2317/31

  multispecific · CPC title